US FDA accepts Ligand's IND application for diabetes drug

Ligand Pharmaceuticals has received US Food and Drug Administration (FDA) approval for its investigational new drug (IND) application for glucagon receptor antagonist programme, and will start clinical development of LGD-6972 for the treatment of typ…
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news